{"id":"sinopharm-bibp","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site pain or swelling"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL332347","moleculeType":"Small molecule","molecularWeight":"473.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) SARS-CoV-2 virus particles, which cannot cause infection but trigger both humoral (antibody) and cellular immune responses. This approach allows the body to develop protective immunity against the virus without risk of active infection. The vaccine is administered intramuscularly in a multi-dose series to establish and maintain protective antibody titers.","oneSentence":"Sinopharm BIBP is a COVID-19 inactivated vaccine that stimulates immune responses against SARS-CoV-2 by presenting inactivated viral particles to the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:44.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults and pediatric populations"}]},"trialDetails":[{"nctId":"NCT05409300","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-25","conditions":"COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection","enrollment":200},{"nctId":"NCT05249816","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine","status":"COMPLETED","sponsor":"Cogna Technology Solutions LLC","startDate":"2022-03-18","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":1000},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT05686161","phase":"PHASE3","title":"mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10-19","conditions":"Immunogenicity, Safety, Efficacy","enrollment":600},{"nctId":"NCT05293665","phase":"PHASE3","title":"Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine","status":"UNKNOWN","sponsor":"Vaxxinity, Inc.","startDate":"2022-03-16","conditions":"COVID-19 Vaccines","enrollment":944},{"nctId":"NCT05162482","phase":"PHASE2","title":"Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID)","status":"UNKNOWN","sponsor":"Aga Khan University Hospital, Pakistan","startDate":"2022-03-01","conditions":"COVID 19 Vaccine","enrollment":1680},{"nctId":"NCT04993560","phase":"","title":"Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-07-18","conditions":"SARS-CoV 2 Infection, Covid19","enrollment":305},{"nctId":"NCT04988048","phase":"PHASE2","title":"Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina","status":"UNKNOWN","sponsor":"Ministry of Public Health, Argentina","startDate":"2021-08-03","conditions":"COVID-19 VACCINE, Covid19","enrollment":1760},{"nctId":"NCT04984408","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-10-01","conditions":"COVID-19 Disease","enrollment":8825}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sinopharm BIBP","genericName":"Sinopharm BIBP","companyName":"Vaxxinity, Inc.","companyId":"vaxxinity-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Sinopharm BIBP is a COVID-19 inactivated vaccine that stimulates immune responses against SARS-CoV-2 by presenting inactivated viral particles to the immune system. Used for COVID-19 prevention in adults and pediatric populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}